News

President and CEO of Cyclacel, Spiro Rombotis, discusses why targeting cyclin-dependent kinases and the DNA repair pathway could enhance care across various oncology indications.

As elections near, politicians in Europe make promises to prioritize the fight against cancer.

FDA leaders urge developers, researchers, and research sponsors to help promote policies and programs to streamline clinical research to develop new medical products at reduced costs.

What small “nudges” can serve as reminders and relevant motivators to help patients meet their goals, talk to a physician, explore a clinical trial, or stick with a treatment?

Click the title above to open the Applied Clinical Trials May 2019 issue in an interactive PDF format.

Transparency in clinical trials doesn't have to be difficult but requires attention writes Thomas Wicks, Chief Strategy Officer for TrialScope. Smaller organizations tend to lag in their commitments to clinical data sharing and be non-compliant with regulations, but the trend is shifting.

Dr. Mark Smith, Chief Medical Officer of VistaGen Therapeutics, sits down with Moe Alsumidaie to discuss the challenges of modern psychiatric clinical trial design and implementation and their neuroactive pherine, PH48B.

Cancer therapy development has advanced to researching targeted immunotherapies and moving into gene-specific therapies. Some companies, however, are focusing on reviving cytotoxic therapies that were too toxic for patients when administered generally. Bill Newell, Chief Executive Officer of Sutro Biopharma, sits down with Moe Alsumidaie to discuss the use of a cell-free protein synthesis approach.

Nonadherence in clinical trials plays a significant role in influencing the quality of data, trial results and, subsequently trial cost and duration. It may stem from unintentional drivers, such as forgetfulness, poor organizational skills, protocol regimen complexity, or experiencing an Adverse Event.